Format

Send to

Choose Destination
Pediatr Blood Cancer. 2019 Jun;66(6):e27721. doi: 10.1002/pbc.27721. Epub 2019 Mar 22.

Hydroxyurea use among children with sickle cell anemia.

Author information

1
Susan B Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.
2
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan.
3
Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
4
Department of Neurology, University of Michigan, Ann Arbor, Michigan.

Abstract

This study describes hydroxyurea use among children ages 1 to 17 with sickle cell anemia (SCA) enrolled in at least one year of Medicaid in six states from 2005 to 2012. Administrative claims were used to summarize the number of days' supply of hydroxyurea dispensed by state and year. A total of 7963 children with SCA contributed 22 424 person-years. Among person-years with greater than 30 days of hydroxyurea, only 18% received at least 300 days of hydroxyurea, which varied by state. Following updated recommendations for all children with SCA to be offered hydroxyurea, strategies to increase hydroxyurea adherence among this population are needed.

KEYWORDS:

Medicaid; administrative claims; hydroxyurea; sickle cell anemia

PMID:
30900800
DOI:
10.1002/pbc.27721

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center